ABOUT US

Corestem is a biopharmaceutical company that researches and commercializes stem cell technology.

History

START-UP AND LEAP
2010
12

Approval of clinical trial in phase 1/2 on ALS stem cell therapy, 'HYNR-CS inj.' (by MFDS and Hanyang University Hospital IRB)

11

Actual inspection of GMP on manufactory of clinical stem cell therapy (at Seongsu-dong factory in Seoul by MFDS)

2007
05

Signed move-in contract in Osong Bio-Health Science Park (with Korea Industrial Complex Corp.)

03

Certification of technology innovation SMEs (INNO-BIZ) (AA grade, by Small and Medium Business Administration)

2006
12

Approved researcher's clinical trial on ALS stem cell therapy (by MFDS and Hanyang University Hospital IRB)

10

Registration of factory (Seongsu-dong, Seoul)

2005
10

Approved use in emergency situations on ALS stem cell therapy (by MFDS and Hanyang University Hospital IRB)

01

Established Biotechnology Research Institute
(with Korea Industrial Technology Association)

2003
12

Established corporation

GROWTH AND DEVELOPMENT
2014
07

Approval of permission of item on ALS stem cell therapy, 'NEURONATA-R inj.' (in MFDS)

05

Completed drug manufacturing permission and actual inspection of GCP relation to permission of item on ALS stem cell therapy, 'NEURONATA-R inj.'

03

Updated confirmation of Venture company (type : a company founded with Venture capital)

02

Accepted application of drug item permission on ALS stem cell therapy, 'NEURONATA-R inj.' (in MFDS)

2013
12

Designated as rare drug and registered on the notification in Ministry of Food and Drug Safety on ALS stem cell therapy, 'NEURONATA-R inj.'

08

Attracted institutional investment for the second time

08

Completed second-phase clinical trial in phase 1/2 on ALS stem cell therapy, 'NEURONATA-R inj.'’ (HYNR-CS inj.)

03

Signed a strategic partnership agreement between Hanlim pharmaceutical and CORESTEM

2012
12

Attracted institutional investment for the first time

10

Completed patient enrollment of second-phase clinical trial in phase 1/2 ’(HYNR-CS) on ALS stem cell therapy, 'HYNR-CS inj.'

2011
11

Completed first-phase clinical trial and Started second-phase clinical trial in phase 1/2 on ALS stem cell therapy, 'HYNR-CS inj.'

03

Signed a strategic partnership agreement between Youyoung pharmaceutical and CORESTEM

01

Started first-phase clinical trial in phase 1/2 on ALS stem cell therapy, 'HYNR-CS inj.'

GO FORWARD
2018
08

Designated as Orphan Drug by US FDA

05

Started first-phase clinical trial on CS10BR05

2017
12

Certificate of GMP Compliance of a Manufacture (at Yong-In factory by MFDS)

06

Designated as research project company of stem cell research in biomedical technology development industry (by Ministry of Science and ICT, Korea)

05

Approval of government task
(Term: 2017.05 ~ 2021.03) Discovery and commercialization of clinical biomarker for efficacy confirmation of stem cell therapy products in SLE (by Ministry of Science and ICT, Korea)

04

Approval of government task
(Term: 2017.04 ~ 2021.12) Global development and commercialization of stem cell-derived extracellular vesicles for intractable neurodegenerative disease (by Ministry of Trade, Industry and Energy, Korea)

04

Designated as Industrial Technology Research Center at the best innovation projects(ATC) (by Ministry of Trade, Industry and Energy, Korea)

04

ChemOn, subsidiary company of CORESTEM, was listed on the KOSDAQ.

2016
11

Approval of government task (Term: 2016.11 ~ 2021.07) Pre-clinical Study and Clinical Trial of Mesenchymal Stem Cell Therapy for Non-Hereditary Cerebellar Ataxia (by Ministry of Health and Welfare, Korea)

11

Designated as 2016 K-Brain Power Company (by Ministry of Trade, Industry and Energy, Korea)

10

Signed MOU for joint research of cell therapy development among Myongji Hospital and CORESTEM

07

Signed a strategic agreement of tech transfer and Joint research and development between Hanlim pharmaceutical and CORESTEM

07

Designated as Type of Innovation Company (by Ministry of Health and Welfare, Korea)

06

Approval of clinical trail in phase 1 on MSA stem cell therapy. ‘CT10BR05’ (by MFDS and Yonsei University Health System Severance Hospital)

2015
06

CORESTEM was listed on the KOSDAQ.

02

Stem cell therapy for Lou Gehrig's disease was administered to a patient for the first time.